Farmacoriflessioni
Tutto quello che il pediatra dovrebbe sapere sul mepolizumab
What paediatricians need to know on mepolizumab
Prisco A, Carlone G, Maschio M, Badina L, Barbi E
Giugno 2021 - pagg. 374 -378 | DOI: 10.53126/MEB40374
Abstract
Mepolizumab, a monoclonal antibody blocking IL-5, is efficacious in the treatment of severe lung diseases sharing eosinophilic inflammation pattern. The paper describes two cases in which the drug was used with excellent results. The first involved a 14-year-old boy with obliterative bronchiolitis, the other an 11-year-old girl with non-atopic asthma. Both cases shared the eosinophilic phenotype of the disease, defined by an eosinophilic count in the peripheral blood equal to or greater than 2% (i.e. a baseline value of 150-200 cells/΅l or 300 cells/΅l during the previous year). Its use demonstrates clinical improvement in severe refractory asthma with eosinophilic phenotype and as off-label drug in obliterative bronchiolitis, leading to a decrease in the rate of exacerbations and enabling the reduction of corticosteroids as well as the resolution of structural anomalies, respectively.
Riassunto
Mepolizumab, un anticorpo monoclonale che blocca l'IL-5, θ efficace nel trattamento di gravi malattie polmonari che condividono un modello di infiammazione eosinofila. L'articolo descrive due casi in cui il farmaco θ stato utilizzato con ottimi risultati. Il primo caso riguarda un ragazzo di 14 anni con bronchiolite obliterante, l'altro una ragazza di 11 anni con asma non atopico. Entrambi i casi condividevano il fenotipo eosinofilo della malattia, definito da una conta eosinofila nel sangue periferico pari o superiore al 2% (ovvero un valore basale di 150-200 cellule/΅l o 300 cellule/΅l durante l'anno precedente). L'uso del mepolizumab dimostra un miglioramento clinico nell'asma grave refrattaria con fenotipo eosinofilo e come farmaco off-label nella bronchiolite obliterante, portando a una diminuzione del tasso di esacerbazioni e consentendo rispettivamente la riduzione dei corticosteroidi e la risoluzione delle anomalie strutturali.
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev 2017;9:CD010834. doi: 10.1002/ 14651858.CD010834.pub3.
2. Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med (Lausanne) 2018;5:49. doi: 10.3389/fmed.2018.00049.
3. Kelly EA, Esnault S, Liu LY, et al. Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma. Am J Respir Crit Care Med 2017;196(11): 1385-95. doi: 10.1164/rccm.201611-2234OC.
4. Martin-Mateos MA. Monoclonal antibodies in pediatrics: use in prevention and treatment. Allergol Immunopathol (Madr) 2007;35(4): 145-50. doi: 10.1157/13108225.
5. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380(9842): 651-9. doi: 10.1016/S0140-6736(12)60988-X.
6. Busse W, Chupp G, Nagase H, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. J Allergy Clin Immunol 2019;143(1):190-200. doi: 10.1016/j.jaci.2018.08.031.
7. Bel EH, Sousa A, Fleming L, et al.; Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011;66 (10):910-7. doi: 10.1136/thx.2010. 153643.
8. Ortega HG, Liu MC, Pavord ID, et al.; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371(13):1198-207. doi: 10.1056/NEJMoa1403290.
9. Bel EH, Wenzel SE, Thompson PJ, et al.; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371(13):1189-97. doi: 10.1056/NEJMoa1403291.
10. Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med 2017; 377(17):1613-29. doi: 10.1056/NEJMoa 1708208.
11. Takeshita Y, Nobuyama S, Kanetsuna Y, et al. Eosinophilic bronchiolitis successfully treated with mepolizumab. J Allergy Clin Immunol Pract 2020;8(3):1159-61. doi: 10.1016/ j.jaip.2019.10.013.
12. Tomyo F, Sugimoto N, Kawamoto M, et al. Anti-interleukin 5 antibody is effective for not only severe asthma and eosinophilic pneumonia but also eosinophilic bronchiolitis. Respirol Case Rep 2018;7(2):e00397. doi: 10.1002/rcr2.397.
13. Gupta A, Ikeda M, Geng B, et al. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol 2019;144(5):1336-42.e7. doi: 10.1016/j.jaci. 2019.08.005.
14. National Institute for Health and Care Excellence. Final appraisal determination: mepolizumab for treating severe refractory eosinophilic asthma. Published Dec 2016.
15. National Institute for Health and Care Excellence. National Institute for Health and Care Excellence. Technology appraisal guidance [TA431]. Published 25 January 2017.
Corrispondenza: giorgiacarlone@gmail.com